Targeting focal adhesion kinase overcomes erlotinib resistance in smoke induced lung cancer by altering phosphorylation of epidermal growth factor receptor

EGFR-based targeted therapies have shown limited success in smokers. Identification of alternate signaling mechanism(s) leading to TKI resistance in smokers is critically important. We observed increased resistance to erlotinib in H358 NSCLC (non-small cell lung carcinoma) cells chronically exposed to cigarette smoke (H358-S) compared to parental cells. SILAC-based mass-spectrometry approach was used to study altered signaling in H358-S cell line. Importantly, among the top phosphosites in H358-S cells we observed hyperphosphorylation of EGFR (Y1197) and non-receptor tyrosine kinase FAK (Y576/577). Supporting these observations, a transcriptomic-based pathway activation analysis of TCGA NSCLC datasets revealed that FAK and EGFR internalization pathways were significantly upregulated in smoking patients, compared to the never-smokers and were associated with elevated PI3K signaling and lower level of caspase cascade and E-cadherin pathways activation. We show that inhibition of FAK led to decreased cellular proliferation and invasive ability of the smoke-exposed cells, and restored their dependency on EGFR signaling. Our data suggests that activation of focal adhesion pathway significantly contributes to erlotinib resistance, and that FAK is a potential therapeutic target for management of erlotinib resistance in smoke-induced NSCLC.

[1]  Y. Bahk,et al.  Clonorchis sinensis excretory-secretory products promote the migration and invasion of cholangiocarcinoma cells by activating the integrin β4-FAK/Src signaling pathway. , 2017, Molecular and biochemical parasitology.

[2]  Daria A. Gaykalova,et al.  In silico analysis of pathways activation landscape in oral squamous cell carcinoma and oral leukoplakia , 2017, Cell Death Discovery.

[3]  O. Eickelberg,et al.  Cigarette smoke alters the secretome of lung epithelial cells , 2017, Proteomics.

[4]  R. Drapkin,et al.  Inhibition of the integrin/FAK signaling axis and c-Myc synergistically disrupts ovarian cancer malignancy , 2017, Oncogenesis.

[5]  A. Aliper,et al.  In silico Pathway Activation Network Decomposition Analysis (iPANDA) as a method for biomarker development , 2016, Nature Communications.

[6]  Nandini A. Sahasrabuddhe,et al.  A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma , 2016, Scientific Reports.

[7]  Nandini A. Sahasrabuddhe,et al.  Chronic exposure to cigarette smoke leads to activation of p21 (RAC1)-activated kinase 6 (PAK6) in non-small cell lung cancer cells , 2016, Oncotarget.

[8]  Quan Zhou,et al.  Activation of the FAK/PI3K pathway is crucial for AURKA-induced epithelial-mesenchymal transition in laryngeal cancer. , 2016, Oncology reports.

[9]  S. Pinto,et al.  Phosphotyrosine profiling of curcumin-induced signaling , 2016, Clinical Proteomics.

[10]  K. Lukong,et al.  Understanding the cellular roles of Fyn-related kinase (FRK): implications in cancer biology , 2016, Cancer and Metastasis Reviews.

[11]  P. Datta,et al.  Effect of Cigarette Smoking on Epithelial to Mesenchymal Transition (EMT) in Lung Cancer , 2016, Journal of clinical medicine.

[12]  S. Batra,et al.  FAK and paxillin, two potential targets in pancreatic cancer , 2016, Oncotarget.

[13]  H. Sekhon,et al.  Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer , 2016, PloS one.

[14]  Hong Chen,et al.  Cigarette smoke extract exposure induces EGFR-TKI resistance in EGFR-mutated NSCLC via mediating Src activation and EMT. , 2016, Lung cancer.

[15]  Wenping Zhou,et al.  14-3-3β Promotes Migration and Invasion of Human Hepatocellular Carcinoma Cells by Modulating Expression of MMP2 and MMP9 through PI3K/Akt/NF-κB Pathway , 2016, PloS one.

[16]  Songbin Fu,et al.  Expression of pY397 FAK promotes the development of non-small cell lung cancer , 2015, Oncology letters.

[17]  Damian Szklarczyk,et al.  STITCH 5: augmenting protein–chemical interaction networks with tissue and affinity data , 2015, Nucleic Acids Res..

[18]  Aarif Ahsan.  Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: An Update. , 2016, Advances in experimental medicine and biology.

[19]  Ming Liu,et al.  Cigarette smoking impairs the response of EGFR-TKIs therapy in lung adenocarcinoma patients by promoting EGFR signaling and epithelial-mesenchymal transition. , 2015, American journal of translational research.

[20]  D. Liebler,et al.  Quantitative Profiling of Protein Tyrosine Kinases in Human Cancer Cell Lines by Multiplexed Parallel Reaction Monitoring Assays* , 2015, Molecular & Cellular Proteomics.

[21]  Srikanth S. Manda,et al.  Phosphoproteomic Analysis Identifies Focal Adhesion Kinase 2 (FAK2) as a Potential Therapeutic Target for Tamoxifen Resistance in Breast Cancer* , 2015, Molecular & Cellular Proteomics.

[22]  P. Visca,et al.  Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer , 2015, Cell Death and Disease.

[23]  M. Clausen,et al.  FDA-approved small-molecule kinase inhibitors. , 2015, Trends in pharmacological sciences.

[24]  Heiner Koch,et al.  Chemical Proteomics Uncovers EPHA2 as a Mechanism of Acquired Resistance to Small Molecule EGFR Kinase Inhibition. , 2015, Journal of proteome research.

[25]  Francesco Petrella,et al.  Non-small-cell lung cancer , 2015, Nature Reviews Disease Primers.

[26]  S. Tomida,et al.  Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal. , 2015, Lung cancer.

[27]  W. Liang,et al.  Impact of smoking status on EGFR-TKI efficacy for advanced non-small-cell lung cancer in EGFR mutants: a meta-analysis. , 2015, Clinical lung cancer.

[28]  S. Ou,et al.  The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomize , 2015, The oncologist.

[29]  Nandini A. Sahasrabuddhe,et al.  Calcium calmodulin dependent kinase kinase 2 - a novel therapeutic target for gastric adenocarcinoma , 2015, Cancer biology & therapy.

[30]  S. Lim,et al.  Understanding the Roles of FAK in Cancer , 2015, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[31]  I. Wistuba,et al.  A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer. , 2014, The oncologist.

[32]  V. Viswanadhan,et al.  Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review , 2014, Expert opinion on therapeutic patents.

[33]  Xiangfan Liu,et al.  New Insights into FAK Phosphorylation Based on a FAT Domain-Defective Mutation , 2014, PloS one.

[34]  K. Sundfeldt,et al.  TGF-β isoforms induce EMT independent migration of ovarian cancer cells , 2014, Cancer Cell International.

[35]  D. Schlaepfer,et al.  FAK in cancer: mechanistic findings and clinical applications , 2014, Nature Reviews Cancer.

[36]  E. Haura,et al.  Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer , 2014, Clinical Cancer Research.

[37]  R. Raja,et al.  Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1α-mediated VEGF-dependent angiogenesis , 2014, Oncogene.

[38]  J. Norman,et al.  FAK Acts as a Suppressor of RTK-MAP Kinase Signalling in Drosophila melanogaster Epithelia and Human Cancer Cells , 2014, PLoS genetics.

[39]  S. Goodman,et al.  The Relative Expression of Mig6 and EGFR Is Associated with Resistance to EGFR Kinase Inhibitors , 2013, PloS one.

[40]  Zimin Liu,et al.  Activation of ERK1/2 and Akt is associated with cisplatin resistance in human lung cancer cells , 2013, Journal of chemotherapy.

[41]  T. Goldkorn,et al.  Src Mediates Cigarette Smoke–Induced Resistance to Tyrosine Kinase Inhibitors in NSCLC Cells , 2013, Molecular Cancer Therapeutics.

[42]  V. Brunton,et al.  E-cadherin–integrin crosstalk in cancer invasion and metastasis , 2013, Journal of Cell Science.

[43]  Johannes Griss,et al.  The Proteomics Identifications (PRIDE) database and associated tools: status in 2013 , 2012, Nucleic Acids Res..

[44]  H. Xi,et al.  Eph receptors and ephrins as targets for cancer therapy , 2012, Journal of cellular and molecular medicine.

[45]  Shuhang Wang,et al.  Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR , 2012, Journal of experimental & clinical cancer research : CR.

[46]  D. Carbone,et al.  Long-term smoking mediated down-regulation of Smad3 induces resistance to carboplatin in non-small cell lung cancer. , 2012, Neoplasia.

[47]  Y. Maehara,et al.  Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation—diversity, ductility, and destiny , 2012, Cancer and Metastasis Reviews.

[48]  M. Sonobe,et al.  Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma. , 2012, Lung cancer.

[49]  T. Goldkorn,et al.  Cigarette Smoke Induces Aberrant EGF Receptor Activation That Mediates Lung Cancer Development and Resistance to Tyrosine Kinase Inhibitors , 2012, Molecular Cancer Therapeutics.

[50]  K. Davies,et al.  Cigarette smoke extract stimulates epithelial-mesenchymal transition through Src activation. , 2011, Free radical biology & medicine.

[51]  E. Raymond,et al.  Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Anticancer Therapy , 2012, Drugs.

[52]  A. Ardizzoni,et al.  Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines , 2011, Molecular Cancer.

[53]  T. Köcher,et al.  Universal and confident phosphorylation site localization using phosphoRS. , 2011, Journal of proteome research.

[54]  D. Wheeler,et al.  Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab , 2011, Cancer biology & therapy.

[55]  A. Chatterjee,et al.  Adenylate Kinase 3 Sensitizes Cells to Cigarette Smoke Condensate Vapor Induced Cisplatin Resistance , 2011, PloS one.

[56]  Richard Z. Liu,et al.  Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity. , 2011, Journal of proteome research.

[57]  N. Kyprianou,et al.  Significance of talin in cancer progression and metastasis. , 2011, International review of cell and molecular biology.

[58]  E. Grande,et al.  The dual kinase complex FAK-Src as a promising therapeutic target in cancer , 2010, OncoTargets and therapy.

[59]  B. O’Malley,et al.  SRC-3Delta4 mediates the interaction of EGFR with FAK to promote cell migration. , 2010, Molecular cell.

[60]  G. Kundu,et al.  Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells. , 2010, Carcinogenesis.

[61]  W. Petty,et al.  Using erlotinib to treat patients with non-small cell lung cancer who continue to smoke. , 2010, Lung cancer.

[62]  Z. Darżynkiewicz,et al.  DNA damage response induced by tobacco smoke in normal human bronchial epithelial and A549 pulmonary adenocarcinoma cells assessed by laser scanning cytometry , 2009, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[63]  R. Lotan,et al.  Expression of the Receptor Tyrosine Kinase EphA2 Is Increased in Smokers and Predicts Poor Survival in Non–Small Cell Lung Cancer , 2009, Clinical Cancer Research.

[64]  S. Lippman,et al.  Lung cancer. , 2008, The New England journal of medicine.

[65]  K. Dittmann,et al.  Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK , 2008, Molecular Cancer.

[66]  Lesley Seymour,et al.  Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  Andrew B. Nobel,et al.  Merging two gene-expression studies via cross-platform normalization , 2008, Bioinform..

[68]  R. Hruban,et al.  Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy. , 2007, Journal of proteome research.

[69]  Laura A. Sullivan,et al.  Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.

[70]  G. Kallergi,et al.  Phosphorylation of FAK, PI-3K, and Impaired Actin Organization in CK-positive Micrometastatic Breast Cancer Cells , 2007, Molecular medicine.

[71]  R. Jove,et al.  Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. , 2006, Cancer research.

[72]  M. Lisanti,et al.  Epidermal Growth Factor Receptor Exposed to Oxidative Stress Undergoes Src- and Caveolin-1-dependent Perinuclear Trafficking* , 2006, Journal of Biological Chemistry.

[73]  William Pao,et al.  Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  J. Rush,et al.  Immunoaffinity profiling of tyrosine phosphorylation in cancer cells , 2005, Nature Biotechnology.

[75]  D. A. Hanson,et al.  Focal adhesion kinase: in command and control of cell motility , 2005, Nature Reviews Molecular Cell Biology.

[76]  R. Nho,et al.  Focal Adhesion Kinase Is Upstream of Phosphatidylinositol 3-Kinase/Akt in Regulating Fibroblast Survival in Response to Contraction of Type I Collagen Matrices via a β1 Integrin Viability Signaling Pathway* , 2004, Journal of Biological Chemistry.

[77]  Z. Darżynkiewicz,et al.  Induction of H2AX Phosphorylation in Pulmonary Cells by Tobacco Smoke: A New Assay for Carcinogens , 2004, Cell cycle.

[78]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[79]  N. Cordes,et al.  Ionizing radiation modules of the expression and tyrosine phosphorylation of the focal adhesion‐associated proteins focal adhesion kinase (FAK) and its substrates p130cas and paxillin in A549 human lung carcinoma cells in vitro , 2003, International journal of radiation biology.

[80]  G. McLean,et al.  Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling , 2002, Nature Cell Biology.

[81]  A. Sorkin,et al.  Effect of Tyrosine Kinase Inhibitors on Clathrin-coated Pit Recruitment and Internalization of Epidermal Growth Factor Receptor* , 2002, The Journal of Biological Chemistry.

[82]  J. Guan,et al.  Phosphorylation of Tyrosine 397 in Focal Adhesion Kinase Is Required for Binding Phosphatidylinositol 3-Kinase* , 1996, The Journal of Biological Chemistry.

[83]  K. Helin,et al.  Internalization and down-regulation of the human epidermal growth factor receptor are regulated by the carboxyl-terminal tyrosines. , 1991, The Journal of biological chemistry.

[84]  K A Overholser,et al.  Multiple autophosphorylation site mutations of the epidermal growth factor receptor. Analysis of kinase activity and endocytosis. , 1991, The Journal of biological chemistry.